2Krug L M, Grant S C, Miller V A, et al. Strategies to eradicate minimal residual disease in cell lung cancer:high dose chemotherapy with autologous bone marrow transplantation, mat rix metalloproteinase inhibitors, and BEC2 plus BCG vaccination[J]. Semin Oncol, 2009, 26:56-61.
3Kozlowski J. This month in investigative urology: Immunotherapy of bladder cancer[J].Int J Urol,2005,162(5):1806-1811.
4Agarwala S S, Kirkwood J M. Adjuvant therapy of melamona[J]. Semin Surg Oncol, 2003,14:302-310.
5Goebel F D, Mannhaher J W, Belshe R B, et al. Recombiant gpl60 as a therapeutic vaccine for HIV-infection:resuh of a large randomized, controlled trial [J]. European Multinational IMMUNO AIDS Vaccine Study Group,2005,13:1461-1468.
6Amara R R, Villinger F. Control of a mucosal challenge and prevention of AIDS by a muhiprotein DNA/MVA vaccine [J]. Science,2001,292:69-74.
7Celis E, Chang T S. HbsAg serum protein complexes stimulate immune T lymphocytes more efficiently than do pure HbsAg[J]. Hepatology,2004,6:1116-1121.
8Ishioka G Y, Fikes J, Hermanson G, et al .Utilization of MHC class transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes [J]. J Immunol,2008,162(7):3915-3925.
9Ayed M, Ben Hassine L, Ben Slama R, et al. Results of BCG in the treatment of Taandp Tlbl addertumors: Evaluation of alone protocol using 75 mg of Pasteurstrain BCG [J]. Prog Urol, 2005,8:206-210.
10Milich D R, Hughes J, Jones J, et al. Conversion of poorlymalaria repeat sequences into ahighly immunogenicvaccine candidate[J].Vaccine,2009,20(56):771-788.
